Evidence map›Paper›PMID 29765164›Full record

SynthesisEuropean journal of clinical nutrition2019

Intake of polyunsaturated fatty acids and risk of preclinical and clinical type 1 diabetes in children-a systematic review and meta-analysis.

Xinliang Liu, Yu Zhang, Hongyan Wu, Ping Zhu, Xianyang Mo, Xiaosong Ma, Jie Ying

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in European journal of clinical nutrition, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xinliang LiuDepartment of Endocrinology, People's Hospital of Xuyi, Xuyi, Jiangsu, P.R. China. xll2017123@sina.com.
Yu ZhangDepartment of Endocrinology, People's Hospital of Xuyi, Xuyi, Jiangsu, P.R. China.
Hongyan WuDepartment of Endocrinology, People's Hospital of Xuyi, Xuyi, Jiangsu, P.R. China.
Ping ZhuDepartment of Endocrinology, People's Hospital of Xuyi, Xuyi, Jiangsu, P.R. China.
Xianyang MoDepartment of Endocrinology, People's Hospital of Xuyi, Xuyi, Jiangsu, P.R. China.
Xiaosong MaDepartment of Infection, People's Hospital of Xuyi, Xuyi, Jiangsu, P.R. China.
Jie YingDepartment of Infection, People's Hospital of Xuyi, Xuyi, Jiangsu, P.R. China.
Xuzhou Medical College · CNXuzhou No.1 People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesThe association between the intake of polyunsaturated fatty acids (PUFAs) and the risk of preclinical and clinical type 1 diabetes (T1D) in children has generated conflicting results. Thus, we aimed to evaluate the definite effects of PUFAs on the risk of preclinical and clinical T1D. SUBJECTS/

methodsThree databases were systematically searched up to July 18, 2017 to identify relevant observational studies, without language restriction. Any study included should report the risk of preclinical or clinical T1D in children with PUFAs supplementation compared with the controls, and report relative risks (RRs) or odds ratios (ORs) or provide data for estimation. Pooled RRs (or ORs) with 95% confidence intervals (CI) were calculated using random-effects models irrespective of statistical heterogeneity assessed by I

resultsWe identified seven studies (three prospective cohort studies and four case-control studies) on PUFAs intake during pregnancy or during early life in children. The pooled RR between the risk of preclinical T1D and n-3 PUFAs supplementation against controls was 0.98 (95%CI, 0.85-1.13), with no heterogeneity. The results were similar after the intake during pregnancy, but not during early life in children (pooled RR, 0.45; 95%CI, 0.21-0.96; P = 0.039). N-3 PUFAs supplementation was not associated with a significant reduction in the risk of clinical T1D in children (pooled RR, 0.87; 95%CI, 0.71-1.08), with substantial heterogeneity(I

conclusionsThe result of the meta-analysis does not support that n-3 or n-6 PUFAs supplementation in children affects the overall risk of preclinical or clinical T1D. However, n-3 PUFAs intake in early life might reduce the risk of preclinical T1D. Therefore, this finding should be verified by more and well-designed prospective research in the future.

Indexed as

Dietary SupplementsCase-Control StudiesChildDiabetes Mellitus, Type 1Fatty Acids, Omega-3Fatty Acids, Omega-6FemaleHumansMaleMaternal Nutritional Physiological PhenomenaOdds RatioPrediabetic StatePregnancyProspective StudiesRisk FactorsFatty Acids, Omega-3Fatty Acids, Omega-6

Identifiers

PMID29765164
OpenAlexW2804441088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.